Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NewLink Begins Renal Immunotherapy Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

NewLink Begins Renal Immunotherapy Trial

Dose-escalation study uses two allogeneic renal cell cancer lines

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

NewLink Genetics has launched a first-in-human Phase I trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. HyperAcute Renal Immunotherapy is comprised of two allogeneic renal cell cancer cell lines engineered to express the murine alpha(1,3)GT gene.

The dose-escalation study is designed primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in as many as 20 patients with recurrent or refractory, metastatic clear-cell renal cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics